Uncontrolled hypertension remains a major health care problem worldwide, being related to a persistently elevated burden of cardiovascular (CV) morbidity and mortality. 1 The clinical benefits obtained by lowering blood pressure (BP) levels to conventional therapeutic targets, namely systolic/diastolic BP less than 140/90 mm Hg for adult hypertensive outpatients and 140-150/90 mm Hg in frail elderly individuals, have been demonstrated in numerous randomized clinical trials 2-5 and confirmed in several independent meta-analyses. [6] [7] [8] On the basis of these evidences, previous sets of both European 9 and US 10 guidelines for hypertension management and control have repeatedly and consistently proposed these goals to be achieved in treated hypertensive patients in a setting of clinical practice.
Uncontrolled hypertension remains a major health care problem worldwide, being related to a persistently elevated burden of cardiovascular (CV) morbidity and mortality. 1 The clinical benefits obtained by lowering blood pressure (BP) levels to conventional therapeutic targets, namely systolic/diastolic BP less than 140/90 mm Hg for adult hypertensive outpatients and 140-150/90 mm Hg in frail elderly individuals, have been demonstrated in numerous randomized clinical trials [2] [3] [4] [5] and confirmed in several independent meta-analyses. [6] [7] [8] On the basis of these evidences, previous sets of both European 9 and US 10 guidelines for hypertension management and control have repeatedly and consistently proposed these goals to be achieved in treated hypertensive patients in a setting of clinical practice.
More recently, the issue on how much lowering systolic BP levels has been questioned by the results of the Systolic Blood Pressure Intervention Trial (SPRINT), 11 a large, randomized, controlled clinical trial performed under the auspices of the National Institute of Health (NIH) in the United States. This trial was aimed at exploring whether the achievement of an ambitious BP target of less than 120 mm Hg for systolic BP would bring any advantage in reducing the risk of CV disease. After a median follow-up of 3.3 years, the trial was early stopped due to a significantly lower rate of the incidence of the primary composite outcome (myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from CV causes), as well as the incidence of all-cause mortality in the intensive-treatment group than in the standard-treatment group. Following these results, new American College of Cardiology/American Heart Association US hypertension guidelines 12 have proposed a new BP classification, which identified patients with stage-1 hypertension in the presence of systolic BP ≥130 and ≤139 mm Hg and diastolic BP ≥80 and ≤89 mm Hg. However, the clinical implications of lower BP thresholds for the hypertension diagnosis and treatment than previously applied remain substantially not estimated or tested.
In the past, we had the possibility to analyze clinical characteristics and global CV risk profile of adult outpatients included in a large, multicenter, observational, clinical survey, performed in Italy. [13] [14] [15] [16] Analyses from this database demonstrated that essential hypertension represented by far the most common CV risk factor with an overall prevalence of about 70% of included adult outpatients and relatively low-control BP rates, mostly for systolic BP. 17 On the basis of these considerations and in view of the large population sample made available by this Italian survey, the primary aim of the present analysis was to evaluate the redistribution of adult outpatients according to either 2003 10 or 2017 12 US hypertension guidelines. Secondary aims of the analysis were to estimate the individual score risk profile of those individuals and to identify proportions of hypertensive patients at high CV risk profile among different BP categories according to different sets of US guidelines.
METHODS

Methodology of the study
The methodology of the study has been previously described. 17 Briefly, the Evaluation of Final Feasible Effect of Control Training and Ultra-Sensitisation survey was designed to evaluate prevalence and control rates of major CV risk factors, as well as diagnostic opportunities and treatment habits of physicians in a setting of real practice in Italy. The program was addressed to physicians operating in both general practice and outpatient clinics across the whole national territory and was aimed at improving quality standards for CV disease management and control. 13 Physicians were invited to participate in an educational training program, aimed at evaluating the efficacy of a clinical problem-oriented learning approach for improving individual global CV risk management in their routine clinical practice. Acceptance of this initial invitation placed physicians under no obligation, and physicians were entitled to drop out of the survey at any stage.
Written invitations were forwarded in a sizable number to ensure a sufficient representative of the study population sample and to achieve this target within a period of approximately 3-4 weeks. For this purpose, each of the 20-24 regional referral centers invited 60 physicians per region (35 general practitioners, 15 cardiologists, and 10 diabetologists) to participate to this survey, for a total of 1,400 individual physicians, selected on the basis of the above-mentioned clinical habits and personal characteristics. Then, approximately 1,250 invitations were issued, and physicians were asked to fill questionnaires featuring their characteristics and practice (age, gender, geographic location, professional expertise, use of electronic database) and to reply anonymously to the administrative site of their regional referral centers.
Following their acceptance, involved physicians were asked to report clinical data extracted from their clinical records from the first 10 consecutive adult Caucasian outpatients aged more than 40 years, whatever the reason they referred to their own attending physicians. The entire data collection was completed by participants on-site and then delivered to the data collection center by online access to remote database. Physicians who completed the program did not receive any compensation for their participation.
Data collection
Data collection included full medical history and physical examination. Information was obtained on current therapy for hypertension, dyslipidemia, diabetes, and concomitant CV diseases and comorbidities, including coronary artery disease, cerebrovascular disease, and peripheral artery disease, as well as any concomitant medication. Based on anthropometric data, calculation was made of body mass index, which was expressed as body weight in kilograms divided by the square of height in meters (kg/m 2 ). Clinic systolic and diastolic BP levels, serum levels of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, glucose, glycosylated hemoglobin (Hbc1A), and creatinine were extracted from available clinical records and generally not exceeding 12 months. Information on electrocardiogram, echocardiogram, carotid or peripheral vascular ultrasound analysis, "fundus oculi" examination, and exercise stress test were also recorded by physicians, when available. Available data were centrally analyzed for global CV risk evaluation and CV risk profile characterization.
The study conformed to the Declaration of Helsinki and its subsequent modifications and was authorized by the reference Ethical Committee. The confidentiality of the data was carefully and strictly protected.
BP stratification
All BP measurements were performed according to international guidelines. 18 For the purposes of the present analysis, the following systolic/diastolic BP strata were considered: (i) 2003 US guidelines 10 : 0 = normal BP (<120/180 mm Hg); 1 = prehypertension (≥120 and ≤139/≥80 and ≤89 mm Hg); 2 = stage-1 hypertension (≥140 and ≤159/≥90 and ≤99 mm Hg); 3 = stage-2 hypertension (≥160/≥100 mm Hg) and (ii) 2017 US guidelines 12 : 0 = normal BP (<120/80 mm Hg); 1 = elevated BP (≥120 and ≤129/<80 mm Hg); 2 = stage-1 hypertension (≥130 and ≤139/≥80 and ≤89 mm Hg); 3 = stage-2 hypertension (≥140/≥90 mm Hg).
Definition of risk factors, markers of organ damage, and comorbidities
At the time of data collection and analysis, 13 diagnosis of hypertension was defined in the presence of systolic BP levels ≥140 mm Hg and/or diastolic BP levels ≥90 mm Hg in untreated subjects or in the presence of stable (≥6 months) antihypertensive drug treatment. 9 Diagnosis of hypercholesterolemia was defined in the presence of total cholesterol levels ≥190 mg/dl or low-density lipoprotein cholesterol levels ≥130 mg/dl while hypertriglyceridemia for triglyceride levels ≥150 mg/dl or stable lipid-lowering drug treatment in both conditions. [19] [20] [21] In addition, low levels of high-density lipoprotein cholesterol levels were defined by ≤40 mg/dl in men and ≤50 mg/dl in women. [19] [20] [21] Obesity was defined in the presence of body mass index ≥25 kg/m 2 . 22 Finally, diabetes was defined in the presence of plasma glucose levels ≥200 mg/dl, or fasting plasma glucose levels ≥126 mg/dl or 2-hour postload glucose ≥200 mg/dl during an oral glucose tolerance test. [23] [24] [25] Cardiac organ damage (OD) was defined by the presence of electrocardiographic left ventricular hypertrophy. 18 Vascular OD was defined by the presence of carotid atherosclerotic plaque, determined by B-mode ultrasonography for intima-media thickness values >1.5 mm. 18 Finally, renal OD was assessed by measuring plasma creatinine concentration and defined by the presence of either estimated glomerular filtration rate less than 60 ml/min per 1.73 m, calculated according to the Cockcroft-Gault formula, or creatinine clearance less than 60 ml/min/1.73m 2 . 18 Coronary artery disease was defined according to the presence of the 2 of the following 3 items: symptoms (e.g., chest pain) lasting longer than 15 minutes, transient increase in serum concentrations of enzymes indicating cardiac damage (more than twice the upper limit of normal) and electrocardiographic changes typical of myocardial infarction (new persistent ST-segment elevation or pathological Q waves in 2 contiguous leads). 26, 27 However, the diagnosis of coronary artery disease may also include other coronary events, for example, acute coronary syndrome, recurrent angina, and coronary revascularization, which were distinguished in the case report form. 28 Peripheral artery disease was defined in the presence of atherosclerotic plaque or lesion in at least 1 artery from all vascular sites, including carotid, vertebral, mesenteric, renal, upper, and lower extremity vessels, causing clinically evident signs or symptoms. 29 Chronic kidney disease was defined in the presence of estimated glomerular filtration rate less than 30 ml/min/1.73m 2 or dialysis. Finally, cerebrovascular disease, namely nonfatal stroke, was defined as a neurological deficit with sudden onset and persistence of symptoms for more than 24 hours or leading to death with no apparent causes other than vascular ones. 30 Transient ischemic attack was defined as a neurological event with the signs and symptoms of stroke but which resolves within a short period of time (typically last 2-30 minutes). 31 Risk score models CV risk was estimated by using US Framingham Risk Score, 32 the 10-year risk of a first atherosclerotic cardiovascular disease (ASCVD) risk, 33 and European SCORE Risk 34 calculators in all patients included in the present analysis.
The US Framingham risk score evaluates the 10-year CV risk of patients aged between 40 and 74 years. 32 Risk factors for morbidity and mortality used by the Framingham scale include age, total cholesterol, high-density lipoprotein cholesterol, and systolic BP as quantitative variables; sex, drug treatment for hypertension, smoking, and history of diabetes mellitus as dichotomous variables. 32 The ASCVD risk score estimates the risk of nonfatal myocardial infarction or coronary heart disease death or fatal or nonfatal stroke over a 10-year period in patients aged between 40 and 74 years. 33 Factors included in this risk score equation are age, gender, race, systolic and diastolic BP, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, history of diabetes, smoking status, antihypertensive therapy, statin, or aspirin therapy. 33 The European SCORE Risk is suitable for the 10-year risk evaluation of patients aged between 40 and 65 years. 34 Risk estimations for developing fatal coronary events are performed by including the total cholesterol level, systolic BP, age, smoking status, and risk levels depending on the regions of Europe. 34 Since study population enrolled adult Caucasian individuals born and living in Italy, the low-risk score charts have been applied to included outpatients.
All these risk tools should be applied in patients without overt CV diseases, while patients with previous CV events have to be classified as very high risk, independently by which risk score systems have been used. According to these recommendations, we have applied the above-mentioned risk scoring systems only to patients without overt CV diseases. In these patients, we have applied the following definitions for individuals with "high CV risk profile": (i) Framingham risk score ≥10, 32 (ii) ASCVD score ≥7, 33 and (iii) European SCORE ≥5. 34 
Statistical analysis
All data were entered into Microsoft Access for Windows (Microsoft Office, Microsoft Corp, Redmond, Wash). Baseline characteristics of patients are presented as number and percentage for dichotomous variables and mean ± SD of the mean for continuous variables. Normal distribution of data was assessed using histograms and KolmogorovSmirnov test. Differences between continuous variables were assessed using analysis of variance test. Categorical variables were compared among groups by the chi-square test. All tests were 2-sided, and a P value of less than 0.05 was considered statistically significant. All calculations were generated using SPSS, version 20.0 (SPSS, Chicago, IL).
RESULTS
Study population
From an overall population sample of 10,012 adult individuals, we selected 8,911 (89.0%) with valid clinic BP data and aged between 40-70 years (44.4% female, age = 60.7 ± 6.6 years, body mass index = 28.2 ± 4.9 kg/m 2 , BP = 136.8 ± 14.5/82.1 ± 8.3 mm Hg, total cholesterol 212.4 ± 40.7 mg/dl). General characteristics of the study population, stratified depending on the presence or the absence of antihypertensive therapy, are reported in Table 1 . Treated hypertensive patients generally showed higher CV risk profile, having more CV risk factors, markers of OD, and other comorbidities, compared with untreated individuals, Abbreviations: ASCVD, 10-year risk of a first atherosclerotic cardiovascular disease; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; TG, triglycerides; TOT-C, total cholesterol. as expected. Yet, they also received more glucose and lipidlowering drugs, as well as more antiplatelet agents than untreated subjects. In particular, among treated hypertensive patients, 4,143 (46.3) received angiotensin-converting enzyme inhibitors, 2,042 (22.9) angiotensin receptor blockers, 1,913 (21.5) β-blockers, 1,923 (21.6) calcium-channel blockers, and 2,541 (28.5) diuretics.
BP stratification
In the overall population, 339 (3.8%) were normotensive. According to 2003 US guidelines, 10 12 On the basis of this new classification, about 37% of individuals with "pre-hypertension" has been reclassified as "stage 1 hypertension, " and 41% with "stage 1" moved to "stage 2" hypertension, respectively (Figure 1) . Similar distributions were found after stratifying study population according to the presence or the absence of antihypertensive therapy. Indeed, in treated hypertensive patients, while 2,457 (36.3%) subjects had prehypertension, the vast majority (61.2%) showed uncontrolled hypertension (47.6% with stage-1 and 13.6% with stage-2 hypertension, respectively) according to 2003 US guidelines. 10 Of note, only 311 (4.6%) patients had elevated BP, while almost all (92.9%) of treated hypertensive patients showed uncontrolled BP levels (31.7% in stage-1 and 61.2% in stage-2 hypertension, respectively), according to 2017 US guidelines. 12 In untreated hypertensive patients, 1,462 (68.2%) had prehypertension, 473 (22.1%) had stage-1, and 34 (1.6%) had stage-2 hypertension according to 2003 guidelines. 10 At the same time, 324 (15.2%) patients had elevated BP, 1,138 (53.3%) had stage-1 and 507 (23.7%) had stage-2 hypertension, according to 2017 US guidelines. 12 
CV risk profile
In the overall population sample, 2,566 (28.8%) outpatients had history of at least 1 major CV event, mostly including peripheral artery disease (n = 879; 9.9%), coronary artery disease (n = 1,859; 20.9%), or cerebrovascular disease (n = 471; 5.3%). As per study protocol, risk score estimations were not calculated in those patients with overt CV disease and applied only to those patients in primary prevention (n = 6,345; 71.2%).
Average risk score estimations obtained with different equations and according to 2003 and 2017 BP classifications are illustrated in Figure 2 for all outpatients in primary prevention and in Figure 3 for the subgroups of patients who did not receive antihypertensive therapies. We observed a significant trend toward increase for both Framingham score, ASCVD score, and European score estimations (P < 0.001 for all comparisons) across different BP strata. Similar findings were observed also in untreated individuals. In particular, in those patients who have been reclassified, average ASCVD score changed from 12.1% in patients with 2003 definition of prehypertension to 9.9% in those with elevated BP and 12.5% in those with stage-1 hypertension according to 2017 US guidelines. 12 Furthermore, significant correlations were observed between ASCVD and Framingham scores (Figure 4) , as well as between ASCVD and European scores ( Figure 5 ), both in the presence or in the absence of antihypertensive therapy.
Finally, proportions of patients in primary prevention with high CV risk profile according to different risk score calculators are reported in Tables 2 and 3 . Of note, the vast proportions of untreated patients in the setting of primary prevention showed BP levels above normal values and risk score estimations above the thresholds required for starting antihypertensive medication, according to 2017 US guidelines BP stratification. 12 
DISCUSSION
Despite an active and long-lasting debate on the BP targets to be achieved under pharmacological and nonpharmacological therapy, the same BP stratification has been maintained for the last 3 decades by both European 9 and US 10 guidelines on hypertension management and control. According to these recommendations, the thresholds of 140/90 mm Hg have been set for many years as the benchmark to distinguish between normotensive individuals and hypertensive patients. The same BP targets have been recommended to be achieved under pharmacological therapies in treated hypertensive patients, with slight differences in frail elderly or in those with diabetes. 9,10 The recent proposal for new BP classification, and especially the lower BP thresholds for hypertension diagnosis, proposed by 2017 US guidelines, 12 has been viewed by many-particularly by lay press-as potentially dangerous. In fact, according to the most recent US guidelines, 12 what is now called stage-1 hypertension was previously defined as "pre-hypertension, " according to 2003 sets of the same guidelines. 10 By reclassifying people formerly considered to have prehypertension as having stage-1 hypertension, these guidelines create a new level of disease, potentially affecting people previously deemed healthy. As an example, a recent analysis estimated that the number of hypertensive patients defined according to 2003 US guidelines 10 of more than 140/90 mm Hg will raise from about 72 to about 103 millions of adult individuals according to new BP thresholds of more than 130/80 mm Hg, as defined by 2017 US guidelines. 12 In other words, about 31 million US adult individuals have been reclassified as hypertensive patients according to new US guidelines. Although this is easy to estimate, there is limited evidence derived from clinical databases collected in a setting of clinical practice, aimed at really estimating which would be the proportions of "new" hypertensive patients.
In our analysis, we were able to demonstrate that about 37% of individuals with "pre-hypertension" has been reclassified as "stage 1 hypertension" and 41% with "stage 1" moved to "stage 2" hypertension, respectively. To our opinion, however, the most relevant aspect is related to the proportions of treated hypertensive patients, who have been reclassified according to 2017 US guidelines. 12 In fact, according to this new BP classification, the vast majority (92.9%) of treated hypertensive patients showed uncontrolled BP levels (31.7% in stage-1 and 61.2% in stage-2 hypertension, respectively). This may have tremendous clinical and socioeconomic implications because it implies the urgent need of implementing effective and well-tolerated antihypertensive strategies, aimed at ameliorating the overall rates of BP control in these hypertensive patients under pharmacological therapies.
On the other hand, the educational intention of new guidelines was that reliance on the new definition of stage-1 hypertension, coupled with the focus on CV risk reduction as assessed with the ACSVD risk calculator, will result in earlier intervention, and ultimately lower CV event rates. 12 In our population sample of untreated individuals, about 53% had stage-1 and 24% had stage-2 hypertension. Of note, the vast proportions of these untreated patients without overt CV diseases, who were predominantly followed in a setting of primary care, showed BP levels above normal values and risk score estimations above the thresholds required for starting antihypertensive medications. In other words, about 3 quarter of untreated patients with BP levels above 130/80 mm Hg also showed high CV risk profile according to either Framingham, ASCVD, or SCORE algorithms, yet they did not receive any antihypertensive medications. Also in this case, new US guidelines may contribute to better identify those individuals with elevated BP levels and high CV risk profile who need to be treated with antihypertensive medications. Such interventions, especially when applied in a setting of primary prevention, may help to reduce the burden of hypertension-related CV diseases and improve eventfree survival rates in hypertensive population.
Potential limitations
The present study is based on a cross-sectional, descriptive survey, and, as such, it can only identify associations, but it cannot provide insights on causation. The most relevant limitation of this analysis was related to the time of data collection, which was ruled out about 10 years ago. In addition, the results presented are to be considered substantially expected as the definition of BP targets to be achieved in the subjects being treated is shifted from values less than 140/90 mm Hg to values less than 120/80 mm Hg. Information on out-of-office BP levels, particularly 24-hour ambulatory BP monitoring, was not available, thus we cannot provide data on proportions of patients with normal (white-coat hypertension) or above normal (sustained hypertension) out-of-office BP. About one-third of normotensive patients received antihypertensive drugs due to CV diseases other than hypertension, as well as to non-CV conditions (e.g., previous myocardial infarction or stroke, renal disease, vascular disease). No data were available for the use of other antihypertensive drug classes, such as α-blockers and antialdosterone agents, which might be considered in difficult to treat hypertension to ameliorate BP control rates.
New BP classification proposed by 2017 US guidelines determined the redistribution of about 37% of individuals from "pre-hypertension" to "stage 1 hypertension" and about 41% from "stage 1" to "stage 2" hypertension, respectively. Of note, the vast majority of treated hypertensive patients showed uncontrolled BP levels (31.7% in stage-1 and 61.2% in stage-2 hypertension, respectively). Redistribution of hypertensive patients according to new US hypertension guidelines compared with older ones may better identify untreated hypertensive patients with above normal BP values and high CV risk profile.
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